



December 2024

## *Evofem Biosciences*

### **Notice Regarding: SOLOSEC® (secnidazole) 2g oral granules National Drug Code Numbers Update and Impact on 340B Virtual Inventory Management**

Evofem has asked the Office of Pharmacy Affairs (OPA) to post this notice on the OPA's public website to notify 340B covered entities that the National Drug Code (NDC) numbers for **SOLOSEC® (secnidazole) 2g oral granules** are being transitioned to new NDCs on/around 2/1/2025 as follows:

These NDC changes *will* be accompanied by product packaging changes including relabeling to reflect the new Manufacturer: Evofem Biosciences, Inc.

Product Description	Old/Existing NDC	New/Replacement NDC	Effective Date
SOLOSEC® (secnidazole) 2g oral granules	27437-0051-01	69751-0400-01	Q1-2025 (expected Feb 1, 2025)

The new NDC(s) will not signify any change in product form, strength, or composition. Because each new Solosec NDC represents the same product as the corresponding old NDC, Evofem Biosciences, Inc. will permit eligible 340B covered entities that use a compliant 340B inventory replenishment model to count accumulations of each old NDC toward replenishment of equal quantities for each corresponding new NDC.

The new NDCs will be available on/around 2/1/2025. Evofem will sell its remaining inventory of each old NDC until it is exhausted, at which point Evofem will begin distributing the corresponding new NDC. Evofem or your distributor will communicate further information regarding the availability of each new NDC. Chargebacks and returns will continue to be processed for the old NDCs.

For any questions regarding this notice contact Evofem: [ssheffield@evofem.com](mailto:ssheffield@evofem.com).

Thank you for your attention.